XML 70 R24.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract]  
Schedules of Concentration of Risk, by Risk Factor
A significant customer is any biopharmaceutical customer, clinical testing payer, or international laboratory partner that represents 10% or more of the Company’s total revenue or accounts receivable balance. Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company’s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company’s total accounts receivable balance, at the respective condensed consolidated balance sheet date, are as follows:
Revenue
Accounts Receivable, Net
Three Months Ended March 31,March 31, 2025December 31, 2024
20252024
(unaudited)(unaudited)
Customer A
***14 %
Customer B
29 %31 %11 %12 %
Customer C
**18 %11 %
*    less than 10%
Schedule of Disaggregation of Revenue
The following table presents the Company’s revenue disaggregated by revenue source:
Three Months Ended March 31,
20252024
(unaudited)
(in thousands)
Oncology$150,559 $125,748 
Biopharma and data
45,376 37,587 
Screening5,677 — 
Licensing and other
1,859 5,156 
Total revenue
$203,471 $168,491